AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 221 filers reported holding AMICUS THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.76 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $937,981 | +4262.9% | 74,680 | -96.1% | 0.00% | -100.0% |
| Q1 2023 | $21,499 | +274.2% | 1,938,583 | +311.9% | 0.01% | +300.0% |
| Q4 2022 | $5,746 | -98.9% | 470,602 | +846.8% | 0.00% | – |
| Q3 2022 | $519,000 | -81.8% | 49,704 | -81.3% | 0.00% | -100.0% |
| Q2 2022 | $2,848,000 | +222.5% | 265,213 | +184.5% | 0.00% | – |
| Q1 2022 | $883,000 | +5.0% | 93,233 | +28.1% | 0.00% | – |
| Q4 2021 | $841,000 | -77.2% | 72,793 | -81.2% | 0.00% | -100.0% |
| Q3 2021 | $3,696,000 | +719.5% | 386,959 | +726.2% | 0.00% | – |
| Q2 2021 | $451,000 | -92.7% | 46,835 | -82.5% | 0.00% | -100.0% |
| Q4 2020 | $6,166,000 | +95.9% | 267,067 | +19.8% | 0.01% | +25.0% |
| Q3 2020 | $3,147,000 | -75.5% | 222,894 | -73.9% | 0.00% | -77.8% |
| Q2 2020 | $12,868,000 | +10.7% | 853,323 | -32.2% | 0.02% | -30.8% |
| Q1 2020 | $11,626,000 | -34.2% | 1,258,174 | -30.7% | 0.03% | +18.2% |
| Q4 2019 | $17,674,000 | +65.8% | 1,814,561 | +36.5% | 0.02% | +29.4% |
| Q3 2019 | $10,661,000 | -21.4% | 1,329,341 | +22.3% | 0.02% | -15.0% |
| Q2 2019 | $13,562,000 | -57.1% | 1,086,682 | -53.3% | 0.02% | -57.4% |
| Q1 2019 | $31,627,000 | +928.5% | 2,325,550 | +624.6% | 0.05% | +840.0% |
| Q4 2018 | $3,075,000 | -69.2% | 320,935 | -51.6% | 0.01% | -61.5% |
| Q1 2018 | $9,976,000 | -47.4% | 663,272 | -49.7% | 0.01% | -50.0% |
| Q4 2017 | $18,974,000 | +419.4% | 1,318,573 | +263.5% | 0.03% | +271.4% |
| Q2 2017 | $3,653,000 | +482.6% | 362,790 | +187.7% | 0.01% | +600.0% |
| Q4 2016 | $627,000 | -14.5% | 126,091 | -6.1% | 0.00% | -50.0% |
| Q2 2016 | $733,000 | +101.4% | 134,247 | +257.7% | 0.00% | +100.0% |
| Q4 2015 | $364,000 | -99.3% | 37,531 | -99.0% | 0.00% | -99.0% |
| Q3 2015 | $52,246,000 | -26.4% | 3,734,506 | -25.6% | 0.10% | -24.6% |
| Q2 2015 | $71,029,000 | +41.4% | 5,019,702 | +8.7% | 0.13% | +44.1% |
| Q1 2015 | $50,232,000 | +68.3% | 4,616,935 | +28.7% | 0.09% | +47.6% |
| Q4 2014 | $29,843,000 | +238.7% | 3,586,910 | +142.2% | 0.06% | +186.4% |
| Q3 2014 | $8,812,000 | +740.0% | 1,481,034 | +371.7% | 0.02% | +633.3% |
| Q2 2014 | $1,049,000 | +126.1% | 313,959 | +57.0% | 0.00% | +200.0% |
| Q3 2013 | $464,000 | -50.2% | 200,000 | -50.0% | 0.00% | -66.7% |
| Q2 2013 | $932,000 | – | 400,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |